~3 spots leftby Jun 2025

tDCS for Cognitive Impairment

LW
DH
Overseen ByDebbie Harrington, CCRP
Age: 18+
Sex: Female
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: University of Pittsburgh
Must not be taking: Anti-epileptic, Neuro-active drugs
Disqualifiers: Gait disorder, Parkinson's, Alzheimer's, others
No Placebo Group
Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

The objective is to evaluate if neuromodulation of the PFC can acutely improve sensory integration for balance performance in OTTBCS.

Will I have to stop taking my current medications?

The trial requires that you are not currently taking anti-epileptic medication. Other medications are not specifically mentioned, so it's best to discuss your current medications with the trial team.

What data supports the effectiveness of this treatment for cognitive impairment?

Research suggests that transcranial direct current stimulation (tDCS) may help improve cognitive functions like processing speed and working memory in people with mood and schizophrenia-spectrum disorders. However, its effects on general cognitive functioning and memory in Alzheimer's disease and mild cognitive impairment are either inconclusive or weak.12345

Is transcranial direct current stimulation (tDCS) safe for humans?

Transcranial direct current stimulation (tDCS) is generally considered safe and well-tolerated in humans, with no reports of serious or lasting harm in over 33,200 sessions. However, it can cause mild skin irritation and, in rare cases, more serious effects, so caution is advised, especially for healthy volunteers.678910

How is the treatment tDCS different from other treatments for cognitive impairment?

Transcranial direct current stimulation (tDCS) is unique because it is a non-invasive method that uses a mild electrical current to stimulate the brain, potentially enhancing cognitive functions like memory and learning. Unlike traditional drug treatments, tDCS does not involve medication and is considered safe and well-tolerated, making it a promising option for conditions like Alzheimer's disease and mild cognitive impairment.1451112

Research Team

BM

Brendan McNeish, MD

Principal Investigator

University of Pittsburgh

Eligibility Criteria

This trial is for women aged 60-85 who are breast cancer survivors (stages I-IIIc), can walk without help, own a device compatible with Fitbit, finished chemotherapy over a year ago, and speak English. They shouldn't have severe neurological diseases except CIPN or CRCD, second cancers, unstable conditions, certain neurodegenerative disorders, recent serious hospitalizations affecting movement or balance.

Inclusion Criteria

I can walk on my own without needing help from devices.
Own a device with capability to sync the Fitbit
I finished my last taxane chemotherapy over a year ago, after turning 60.
See 5 more

Exclusion Criteria

I cannot stand or walk by myself for a minute.
I have received immunotherapy in the past.
Any unstable medical condition
See 9 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive active tDCS or sham tDCS to evaluate its effect on balance performance

8 months
3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 months

Treatment Details

Interventions

  • Sham tDCS (Behavioural Intervention)
  • transcranial direct current stimulation (tDCS) (Neuromodulation)
Trial OverviewThe study tests if stimulating the brain's PFC with tDCS can immediately improve how well older breast cancer survivors maintain their balance by processing sensory information better compared to sham (fake) treatment.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Sham tDCS, then Active tDCSExperimental Treatment2 Interventions
Sham will be delivered in visit 2. Stimulation (tDCS) will be delivered in visit 3.
Group II: Active tDCS, then Sham tDCSExperimental Treatment2 Interventions
Stimulation (tDCS) will be delivered in visit 2. Sham will be delivered in visit 3.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Pittsburgh

Lead Sponsor

Trials
1,820
Recruited
16,360,000+

Findings from Research

Transcranial direct current stimulation (tDCS) is a safe and noninvasive method that shows promise in treating cognitive decline associated with Alzheimer's disease and mild cognitive impairment.
The review highlights the need for further large-scale clinical trials to better understand the mechanisms of tDCS and improve its application in clinical settings.
Potential of Transcranial Direct Current Stimulation in Alzheimer's Disease: Optimizing Trials Toward Clinical Use.Pilloni, G., Charvet, LE., Bikson, M., et al.[2022]
Anodal transcranial direct current stimulation (tDCS) applied to the left dorsolateral prefrontal cortex significantly improved cognitive tasks related to processing speed, selective attention, and planning in five older adults with mild cognitive impairment (MCI).
The study suggests that combining tDCS with cognitive stimulation programs may enhance cognitive performance in individuals with MCI, but further research is needed to explore long-term effects and practical applications in daily life.
The Effects of Transcranial Direct Current Stimulation on the Cognitive Functions in Older Adults with Mild Cognitive Impairment: A Pilot Study.Cruz Gonzalez, P., Fong, KNK., Brown, T.[2022]
Transcranial direct current stimulation (tDCS) has shown potential to improve cognitive functions such as processing speed, working memory, and executive functions in patients with mood disorders and schizophrenia, based on a systematic review of 41 studies.
The effects of tDCS on cognitive functioning and memory in Alzheimer's disease and mild cognitive impairment are less clear, with evidence being inconclusive or weak, highlighting the need for standardized protocols in future research.
Transcranial Direct Current Stimulation and Cognition in Neuropsychiatric Disorders: Systematic Review of the Evidence and Future Directions.Ciullo, V., Spalletta, G., Caltagirone, C., et al.[2022]

References

Potential of Transcranial Direct Current Stimulation in Alzheimer's Disease: Optimizing Trials Toward Clinical Use. [2022]
The Effects of Transcranial Direct Current Stimulation on the Cognitive Functions in Older Adults with Mild Cognitive Impairment: A Pilot Study. [2022]
Transcranial Direct Current Stimulation and Cognition in Neuropsychiatric Disorders: Systematic Review of the Evidence and Future Directions. [2022]
Effects of multisession transcranial direct current stimulation as an augmentation to cognitive tasks in patients with neurocognitive disorders in Japan: a study protocol for a randomised controlled trial. [2021]
Safety and Feasibility of Transcranial Direct Current Stimulation for Cognitive Rehabilitation in Patients With Mild or Major Neurocognitive Disorders: A Randomized Sham-Controlled Pilot Study. [2022]
Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. [2022]
A Systematic Review on the Acceptability and Tolerability of Transcranial Direct Current Stimulation Treatment in Neuropsychiatry Trials. [2018]
Safety of transcranial direct current stimulation in healthy participants. [2021]
Microdermabrasion facilitates direct current stimulation by lowering skin resistance. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Tolerability and blinding of 4x1 high-definition transcranial direct current stimulation (HD-tDCS) at two and three milliamps. [2020]
11.United Statespubmed.ncbi.nlm.nih.gov
Effects of Transcranial Direct Current Stimulation on Memory of Elderly People with Mild Cognitive Impairment or Alzheimer's Disease: A Systematic Review. [2022]
Enhancing Immediate Memory, Potential Learning, and Working Memory with Transcranial Direct Current Stimulation in Healthy Older Adults. [2023]